{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T16:17:46Z","timestamp":1783181866689,"version":"3.54.6"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013220","name":"Ultragenyx Pharmaceutical Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013220","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.atherosclerosis.2026.120657","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:51:11Z","timestamp":1770191471000},"page":"120657","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Efficacy of evinacumab by genotype and low-density lipoprotein receptor function in patients with homozygous familial hypercholesterolaemia: A subanalysis from the ELIPSE open-label extension study"],"prefix":"10.1016","volume":"414","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9170-7938","authenticated-orcid":false,"given":"Frederick J.","family":"Raal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Greber-Platzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurens F.","family":"Reeskamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Iannuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Rosenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Saheb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Stefanutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Stroes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Bruckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpana","family":"Waldron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poulabi","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Pordy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinay","family":"Kainth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gaudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.atherosclerosis.2026.120657_bib1","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"Update on european atherosclerosis society consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance","volume":"44","author":"Cuchel","year":"2023","journal-title":"Eur Heart J"},{"issue":"32","key":"10.1016\/j.atherosclerosis.2026.120657_bib2","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the consensus panel on familial hypercholesterolaemia of the european atherosclerosis society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2026.120657_bib3","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/eurjpc\/zwab224","article-title":"Major adverse cardiovascular events in homozygous familial hypercholesterolaemia: a systematic review and meta-analysis","volume":"29","author":"Kramer","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120657_bib4","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.atherosclerosis.2018.06.859","article-title":"Familial hypercholesterolemia treatments: guidelines and new therapies","volume":"277","author":"Raal","year":"2018","journal-title":"Atherosclerosis"},{"issue":"10326","key":"10.1016\/j.atherosclerosis.2026.120657_bib5","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(21)02001-8","article-title":"Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study","volume":"399","author":"Tromp","year":"2022","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2026.120657_bib6","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.029175","article-title":"Contemporary homozygous familial hypercholesterolemia in the United States: insights from the CASCADE FH registry","volume":"12","author":"Cuchel","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"19","key":"10.1016\/j.atherosclerosis.2026.120657_bib7","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.jacc.2025.04.005","article-title":"Homozygous familial hypercholesterolemia is a life-limiting condition: medical life-trajectories in the Post-2010 era","volume":"85","author":"Mulder","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120657_bib8","series-title":"Endotext [Internet]","article-title":"Familial hypercholesterolemia: genes and beyond","author":"Warden","year":"2000"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2026.120657_bib9","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/humu.1380010602","article-title":"Molecular genetics of the LDL receptor gene in familial hypercholesterolemia","volume":"1","author":"Hobbs","year":"1992","journal-title":"Hum Mutat"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.120657_bib10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41569-018-0052-6","article-title":"The complex molecular genetics of familial hypercholesterolaemia","volume":"16","author":"Berberich","year":"2019","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2026.120657_bib11","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/MOL.0000000000000863","article-title":"Genotype-phenotype correlation in a large cohort of pediatric patients with heterozygous and homozygous familial hypercholesterolemia","volume":"34","author":"Reijman","year":"2023","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2026.120657_bib12","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.atherosclerosis.2020.08.027","article-title":"Homozygous familial hypercholesterolemia in Italy: clinical and molecular features","volume":"312","author":"Bertolini","year":"2020","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.120657_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9010219","article-title":"A real-world experience of clinical, biochemical and genetic assessment of patients with homozygous familial hypercholesterolemia","volume":"9","author":"Di Taranto","year":"2020","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2026.120657_bib14","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1161\/CIRCGENETICS.116.001545","article-title":"Homozygous familial hypercholesterolemia in Spain: prevalence and phenotype-genotype relationship","volume":"9","author":"Sanchez-Hernandez","year":"2016","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.atherosclerosis.2026.120657_bib15","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.atherosclerosis.2016.03.009","article-title":"Phenotype diversity among patients with homozygous familial hypercholesterolemia: a cohort study","volume":"248","author":"Raal","year":"2016","journal-title":"Atherosclerosis"},{"issue":"15","key":"10.1016\/j.atherosclerosis.2026.120657_bib16","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1093\/eurjpc\/zwae144","article-title":"Current treatments for the management of homozygous familial hypercholesterolaemia: a systematic review and commentary","volume":"31","author":"Gu","year":"2024","journal-title":"Eur J Prev Cardiol"},{"issue":"9965","key":"10.1016\/j.atherosclerosis.2026.120657_bib17","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2026.120657_bib18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacc.2020.05.027","article-title":"Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: the ODYSSEY HoFH trial","volume":"76","author":"Blom","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.120657_bib19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2026.120657_bib20","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41569-024-01039-5","article-title":"The LDL cumulative exposure hypothesis: evidence and practical applications","volume":"21","author":"Ference","year":"2024","journal-title":"Nat Rev Cardiol"},{"issue":"27","key":"10.1016\/j.atherosclerosis.2026.120657_bib28","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/eurheartj\/ehae325","article-title":"Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy","volume":"45","author":"Gaudet","year":"2024","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2026.120657_bib29","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2026.120657_bib30","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1161\/ATVBAHA.119.313051","article-title":"Functional analysis of LDLR (low-density lipoprotein receptor) variants in patient lymphocytes to assess the effect of evinacumab in homozygous familial hypercholesterolemia patients with a spectrum of LDLR activity","volume":"39","author":"Banerjee","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2026.120657_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100060","article-title":"Existing and emerging therapies for the treatment of familial hypercholesterolemia","volume":"62","author":"Rosenson","year":"2021","journal-title":"J Lipid Res"},{"issue":"14","key":"10.1016\/j.atherosclerosis.2026.120657_bib32","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/eurheartj\/ehx317","article-title":"Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol","volume":"39","author":"Thompson","year":"2018","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2026.120657_bib33","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13836","article-title":"Evinacumab: mechanism of action, clinical, and translational science","volume":"17","author":"Dingman","year":"2024","journal-title":"Clin Transl Sci"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2026.120657_bib34","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jacl.2021.10.003","article-title":"Evolocumab in patients with homozygous familial hypercholesterolemia in India","volume":"15","author":"Bansal","year":"2021","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2026.120657_bib35","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jacc.2019.12.020","article-title":"Long-term evolocumab in patients with familial hypercholesterolemia","volume":"75","author":"Santos","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2026.120657_bib36","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S2213-8587(24)00347-4","article-title":"Protein-binding therapy: a new approach to lower cholesterol","volume":"13","author":"Hegele","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2026.120657_bib37","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S2213-8587(24)00313-9","article-title":"Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial","volume":"13","author":"Raal","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2026.120657_bib38","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.122.063460","article-title":"Efficacy, safety, and tolerability of inclisiran in patients with homozygous familial hypercholesterolemia: results from the ORION-5 randomized clinical trial","volume":"149","author":"Raal","year":"2024","journal-title":"Circulation"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026000237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026000237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T17:58:27Z","timestamp":1773856707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915026000237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":31,"alternative-id":["S0021915026000237"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.120657","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of evinacumab by genotype and low-density lipoprotein receptor function in patients with homozygous familial hypercholesterolaemia: A subanalysis from the ELIPSE open-label extension study","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.120657","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120657"}}